CompletedNot Applicable

Real-life Data of Constitutional Von Willebrand Disease in Western France

France922 participantsStarted 2023-07-07

Plain-language summary

The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center. The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Constitutional Von Willebrand Disease patient, of any severity, with or without Von Willebrand Factors inhibitors * Patient included in the research database BERHLINGO * Patient treated or not by desmopressin or Von Willebrand Factor/FVIII/by-passing agents available on the French market (at baseline) * Patient who agrees to participate in the HOPSCOTcH-Will II and followed in one of the 5 investigator centers Exclusion Criteria: \- Patients under guardianship

What they're measuring

Observational study, description of the global therapeutic modalities required for severe treated hemorrhagic events in constitutional Von Willebrand Disease patients of any severity

Timeframe: 4 years

Trial details

NCT IDNCT04887324

SponsorNantes University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Von Willebrand Diseases trials